Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00089791
Status:
COMPLETED
Last Update Posted:
2022-11-08
First Post:
2004-08-13
Brief Title:
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None